Literature DB >> 8188616

Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity.

N Sasagasako1, T Kobayashi, Y Yamaguchi, N Shinnoh, I Goto.   

Abstract

The metabolism of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) was studied using cultured fibroblasts deficient in acid beta-glucosidase activity. In fibroblasts from patients with Gaucher's disease, in vitro beta-glucosidase activities were 2.7-11.7% and 4.8-13.6% of control values when 4-methylumbelliferyl beta-D-glucoside and GlcSph were used as substrates, respectively. In spite of the enzyme deficiency, GlcCer and GlcSph, the natural substrates of the deficient enzyme, did not accumulate in the cells. When normal fibroblasts were incubated with conduritol B epoxide (CBE), a specific inhibitor of acid beta-glucosidase, the in vitro enzyme activities decreased dose-dependently (2.2-2.4% of control values at 50 microM CBE), and GlcCer and GlcSph accumulated in the cells at concentrations of CBE higher than 50 microM. To investigate the intracellular metabolism of GlcCer and GlcSph, either radioactive GlcCer or GlcSph was loaded onto cultured fibroblasts. In fibroblasts treated with a high dose of CBE (1 mM), the degradation of GlcCer and GlcSph was retarded (5-21% on day 7; normal range, 81-99%), while in fibroblasts from patients with Gaucher's disease, both the pattern and rate of the degradation of the lipids (83-97% on day 7) were almost the same as those seen in the control cells. These results indicate that in Gaucher's disease fibroblasts the intracellular metabolism of GlcCer and GlcSph is normal in spite of the deficiency in beta-glucosidase activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188616     DOI: 10.1093/oxfordjournals.jbchem.a124284

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  8 in total

1.  Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease.

Authors:  Pramod K Mistry; Jun Liu; Li Sun; Wei-Lien Chuang; Tony Yuen; Ruhua Yang; Ping Lu; Kate Zhang; Jianhua Li; Joan Keutzer; Agnes Stachnik; Albert Mennone; James L Boyer; Dhanpat Jain; Roscoe O Brady; Maria I New; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

Review 2.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

Review 3.  Modeling neuronopathic storage diseases with patient-derived culture systems.

Authors:  Friederike Zunke; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2019-02-19       Impact factor: 5.996

4.  Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy.

Authors:  Marcia R Terluk; Julianne Tieu; Siddhee A Sahasrabudhe; Ann Moser; Paul A Watkins; Gerald V Raymond; Reena V Kartha
Journal:  Neurotherapeutics       Date:  2022-04-04       Impact factor: 6.088

5.  Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity.

Authors:  Christopher J Folts; Nicole Scott-Hewitt; Christoph Pröschel; Margot Mayer-Pröschel; Mark Noble
Journal:  PLoS Biol       Date:  2016-12-15       Impact factor: 8.029

6.  Assessment of cellular cobalamin metabolism in Gaucher disease.

Authors:  Suelen Porto Basgalupp; Marina Siebert; Charles Ferreira; Sidney Behringer; Ute Spiekerkoetter; Luciana Hannibal; Ida Vanessa Doederlein Schwartz
Journal:  BMC Med Genet       Date:  2020-01-13       Impact factor: 2.103

7.  Unfolded protein response in Gaucher disease: from human to Drosophila.

Authors:  Gali Maor; Sigal Rencus-Lazar; Mirella Filocamo; Hermann Steller; Daniel Segal; Mia Horowitz
Journal:  Orphanet J Rare Dis       Date:  2013-09-11       Impact factor: 4.123

8.  Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.

Authors:  Shoshana Revel-Vilk; Maria Fuller; Ari Zimran
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.